// App-Quantinova.ai

14931 : Low-Dose Prasugrel Has Prognostic Superiority to Clopidogrel in High-Bleeding Risk Patients Undergoing Contemporary Percutaneous Coronary Intervention

Researchers

Presenter

  • Takuro Abe

Principal Investigators

  • Kentaro Jujo

  • Takehiro Hata

  • KAZUHO KAMISHIMA

  • Hiroshi Koganei

  • Tomohiro Sakamoto

  • Junichi Yamaguchi

  • Nobuhisa Hagiwara

Medical Centers

  • NISHIARAI HEART CENTER HOSPITAL, Tokyo, Japan

  • TOKYO WOMENS MEDICAL UNIVERSITY MEDICAL CENTER EAST, Tokyo, Japan

  • Saiseikai Kurihashi Hospital, Kuki, Japan

  • Kosei Hosp, Tokyo, Japan

  • Ogikubo Hospital, Tokyo, Japan

  • SAISEIKAI KUMAMOTO HOSPITAL, Kumamoto City, Japan

  • TOKYO WOMEN'S MEDICAL UNIVERSITY, Tokyo, Japan

  • TOKYO WOMEN'S MEDICAL UNIVERSITY, Tokyo, Japan

Locations

  • Japan

Companies

  • N/A

Study Components

Therapeutic Area

  • Central Nervous System (CNS)

Disease

  • Acute Coronary Syndromes

  • Congestive heart failure

  • Venous thrombosis

  • Stroke

Biomarkers

  • N/A

Drug/Treatment

  • Clopidogrel bisulfate

  • Prasugrel

  • Aspirin

  • Albyl-E

Outcome

  • N/A

Study Design

  • Superiority

  • Prospective

  • Cohort

Phase

  • II

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved